Experimental drug pacritinib tested for returning prostate cancer – but trial stopped early
NCT ID NCT04635059
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited information on how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pacritinib (an oral drug taken daily)
What this could lead to
If it works, this could point toward a way to delay cancer progression in men whose prostate cancer has returned after initial treatment.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not effectively control the cancer or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States